GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice

Regulatory Peptides

Volumn 169, Issue 1-3, 2011, Pages 43-48

  Tomas, Eva ^a   Wood, Jenna A ^a   Stanojevic, Violeta ^a   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Energy expenditure; Glucagon like peptide 1; Insulin resistance; Obesity

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [28-36] AMIDE; GLUCOSE; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; ENERGY EXPENDITURE; FATTY LIVER; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW FAT DIET; MALE; METABOLIC SYNDROME X; MOUSE; MOUSE MUTANT; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; EATING; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; OBESITY; PEPTIDE FRAGMENTS; TRIGLYCERIDES; WEIGHT GAIN;

MUS;

EID: 79958011891     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.04.006     Document Type: Article

References (27)

1. Grattagliano I., Palmieri V.O., Portincasa P., Moschetta A., Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008, 19:491-504.
2. Haas J.T., Biddinger S.B. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009, 20:206-210.
3. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35years. Diabetes Metab Rev 1998, 14:263-283.
4. Tappy L. Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Diabetes Metab 1995, 21:233-240.
5. Beck-Nielsen H., Hother-Nielsen O., Staehr P. Is hepatic glucose production increased in type 2 diabetes mellitus?. Curr Diab Rep 2002, 2:231-236.
6. Stein L.L., Dong M.H., Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009, 26:893-907.
7. Watanabe S., Yaginuma R., Ikejima K., Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008, 43:509-518.
8. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
9. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20:876-913.
10. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94:1843-1852.
11. Tomas E., Habener J.F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010, 2159-2167.
12. Elahi D., Egan J.M., Shannon R.P., Meneilly G.S., Khatri A., Habener J.F., Andersen D.K. Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity 2008, 16:1501-1509.
13. Tomas E., Stanojevic V., Habener J.F. GLP-1(9-36)amide metabolite and suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 2010, 42:657-662.
14. Tomas E., Stanojevic V., Wood J.A., Habener J.F. GLP-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab 2011, 13:26-33.
15. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., Göke R., Göke B., Thole H., Zimmermann B., Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995, 58:149-156.
16. Plamboeck A., Holst J.J., Carr R.D., Deacon C.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005, 48:1882-1890.
17. Tomas E., Stanojevic V., Habener J.F. GLP-1-Derived Nonapeptide GLP-1(28-36)amide Targets To Mitochondria and Suppresses Glucose Production and Oxidative Stress in Isolated Mouse Hepatocytes. Regul Pept 2011, 167(2-3):177-184.
18. Zhang J., Tokui Y., Yamagata K., Kozawa J., Sayama K., Iwahashi H., Okita K., Miuchi M., Konya H., Hamaguchi T., Namba M., Shimomura I., Miyagawa J.I. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 2007, 50:1900-1999.
19. Parekh P.I., Petro A.E., Tiller J.M., Feinglos M.N., Surwit R.S. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 1998, 47:1089-1096.
20. Standeven K.F., Hess K., Carter A.M., Rice G.I., Cordell P.A., Balmforth A.J., Lu B., Scott D.J., Turner A.J., Hooper N.M., Grant P.J. Neprilysin, obesity and the metabolic syndrome. Int J Obes 2010, 1-10.
21. Ryan A.S., Egan J.M., Habener J.F., Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 1998, 83:2399-2404.
22. Vahl T.P., Paty B.W., Fuller B.D., Pridgeon R.L., D'Alession D.A. Effects of GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003, 88:1772-177921.
23. Rolin B., Deacon C.F., Carr R.D., Ahrén B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 2004, 494:283-288.
24. Egan J.M., Meneilly G.S., Habener J.F., Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002, 87:3768-3773.
25. Raab E.L., Vuguin P.M., Stoffers D.A., Simmons R.A. Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1785-R1794.
26. Samson S.L., Gonzalez E.V., Yechoor V., Bajaj M., Oka K., Chan L. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 2008, 16:1805-1812.
27. Aviv V., Meivar-Levy I., Rachmut I.H., Rubinek T., Mor E., Ferber S. Exendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiation. J Biol Chem 2009, 264:33509-33520.